Your browser doesn't support javascript.
loading
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Massacesi, Cristian; Di Tomaso, Emmanuelle; Urban, Patrick; Germa, Caroline; Quadt, Cornelia; Trandafir, Lucia; Aimone, Paola; Fretault, Nathalie; Dharan, Bharani; Tavorath, Ranjana; Hirawat, Samit.
Affiliation
  • Massacesi C; Novartis Oncology, Paris, France.
  • Di Tomaso E; Novartis Institutes for BioMedical Research Inc, Cambridge, MA, USA.
  • Urban P; Novartis Pharma AG, Basel, Switzerland.
  • Germa C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Quadt C; Novartis Pharmaceuticals KK, Tokyo, Japan.
  • Trandafir L; Novartis Oncology, Paris, France.
  • Aimone P; Novartis Pharma AG, Basel, Switzerland.
  • Fretault N; Novartis Oncology, Paris, France.
  • Dharan B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Tavorath R; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Hirawat S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Onco Targets Ther ; 9: 203-10, 2016.
Article in En | MEDLINE | ID: mdl-26793003
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Onco Targets Ther Year: 2016 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Onco Targets Ther Year: 2016 Document type: Article Affiliation country: Country of publication: